ASLAN licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology and inflammation diseases, and uses resources available across Asia to progress the drugs through clinical development. Proceeds from the Series B will be used to fund ongoing clinical development of ASLAN’s portfolio, including the phase 2b program for a small-molecule inhibitor being developed for gastric cancer. The financing will also support licensing additional compounds this year and next.